Xcout Intel
ATP-Bio
ATP-Bio is a collaborative biotechnology research network headquartered at the University of Minnesota in Minneapolis, focusing on advanced technologies for the preservation of biological systems.
Subscribe to see ATP-Bio’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
ATP-Bio at a glance
ATP-Bio is a biotechnology and healthcare company headquartered in United States. Xcout tracks 24 named people at ATP-Bio, including Dan Chen (Strategic Partners & Innovation (SPI) Director).
ATP-Bio leadership
- Dan ChenStrategic Partners & Innovation (SPI) Director
- Guadalupe RuizDirector of Transfer Student Initiatives & Professional Development
- John BischofATP-Bio Director
- Korkut UygunResearch Pillar Director
- Mehmet TonerATP-Bio Deputy Director
- Rhonda FranklinIntegration Director / EWD Pillar Director
18 more named people on record for ATP-Bio, with roles, board committees and tenure — see the full roster →
ATP-Bio competitors
A few of ATP-Bio's closest competitors — see the full list of competitors and alternatives →
Primal Therapies, Inc. is a biotechnology company specializing in microbial technology and expertise, with its primary location in Minneapolis, Minnesota.
General BioTechnology LLC provides biomedical research, specializing in the development of cryo-preservation and banking methods for diverse cells.
CryoStasis is a biotechnology company headquartered in Ottawa, Canada, specializing in the subzero unfrozen bio-preservation of cells, tissues, and organs.
Luminary Therapeutics, Inc. is a pre-clinical stage cell therapy development company located in Minneapolis, Minnesota, focused on creating non-viral cell therapies.
Rapid Diagnostek, Inc. was an emerging medical device company headquartered in the Minneapolis-St. Paul area of Minnesota. The company developed wireless biosensors and medical diagnostic technology.
Sanford Biosciences is an independent, not-for-profit research institute that advances RNA biology to discover and develop next-generation RNA-based medicines. Operating between academic discovery and industry development, the institute moves research programs from early science through proof-of-concept before partnering with biopharma and start-up companies to advance them.
Get ATP-Bio's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on ATP-Bio in Xcout Intel
- 24 named people with titles, LinkedIn and board committees
- The full competitor set, tracking, exports and API access